Deep Track Capital’s Relmada Therapeutics RLMD Stock Holding History

Deep Track Capital’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-674,833	Closed	-$2.19M	–	77
2024 Q3	$2.19M	Sell	674,833 -559,940	-45%	-$1.81M	0.07%	67
2024 Q2	$3.7M	Sell	1,234,773 -5,261	-0.4%	-$19K	0.11%	60
2024 Q1	$5.77M	Sell	1,240,034 -804,473	-39%	-$3.88M	0.17%	59
2023 Q4	$8.46M	Sell	2,044,507 -793,311	-28%	-$2.35M	0.28%	53
2023 Q3	$8.51M	Hold	2,837,818	–	–	0.33%	52
2023 Q2	$6.98M	Hold	2,837,818	–	–	0.32%	46
2023 Q1	$6.41M	Hold	2,837,818	–	–	0.26%	48
2022 Q4	$9.9M	Buy	2,837,818 +2,376,957	+516%	+$20.9M	0.42%	45
2022 Q3	$17.1M	Sell	460,861 -39,139	-8%	-$1.08M	0.78%	45
2022 Q2	$9.49M	Buy	500,000 +397,883	+390%	+$8.68M	0.62%	38
2022 Q1	$2.76M	Buy	+102,117	New	+$2.11M	0.18%	47

Other funds holding RLMD

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Deep Track Capital's RLMD Position: Q4 2024 in Review

Deep Track Capital sold out of Relmada Therapeutics (RLMD) in Q4 2024, closing a stake of 674,833 shares — an estimated $2.19M sold.

Deep Track Capital first reported a position in RLMD in Q1 2022 and held it in 11 quarters. The position peaked at $17.1M in Q3 2022. 48 funds tracked by Wall St. Rank hold RLMD as of Q4 2024.

Deep Track Capital reported no remaining Relmada Therapeutics position as of Q4 2024 after selling out during the quarter.
Deep Track Capital sold 674,833 Relmada Therapeutics shares in Q4 2024, an estimated $2.19M.
Deep Track Capital first reported a position in Relmada Therapeutics in Q1 2022 and held it in 11 quarters.
Deep Track Capital's Relmada Therapeutics position peaked at $17.1M in Q3 2022.
48 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2024.

Based on Deep Track Capital's 13F filing for Q4 2024, filed 14 Feb 2025.